Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News
September 11th 2024

Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee

September 10th 2024

Different Options for Different People: Dr Bellinda King-Kallimanis Explores the State of Patient Education in Lung Cancer

September 6th 2024

Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC

August 8th 2024

Late-Stage Vibostolimab, Pembrolizumab Plus Chemotherapy Trial Discontinued Due to Adverse Events

May 31st 2024

Shared Decision-Making for Lung Cancer Screening: More Straw for the Camel’s Back

Video Interviews
View All
December 21st 2023

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

November 22nd 2023

Dr Mark Socinski Discusses the Impacts of Immunotherapy on Lung Cancer Outcomes

November 10th 2023

Dr Mark Socinski on the Heterogeneity of Lung Cancer and Targeted Treatment

November 5th 2023

Dr Robert Daly on Benefits of At-Home Lung Cancer Treatment

October 25th 2023

Dr Erin Gillaspie Explores Lung Cancer Surgery Evolution

October 2nd 2023

Dr Erin Gillaspie Discusses New Lung Cancer Developments, Surgery Technologies

September 20th 2023

Dr Erin Gillaspie Explains How to Discover Best Treatments for Patients With Lung Cancer

September 6th 2023

Dr Erin Gillaspie Discusses Lung Cancer Outcome Improvements

May 28th 2023

Dr Mark Socinski Discusses the Cost-effectiveness of Biomarker Testing in NSCLC

May 4th 2023

For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski

Podcasts
View All
September 24th 2023

Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation

More News

Doctor with health care icons and FDA | Image credit: wladimir1804 - stock.adobe.com
May 17th 2024

Tarlatamab Receives Accelerated Approval for Extensive-Stage SCLC

Laura Joszt, MA
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
Top 5 Most-Read Lung Cancer Articles of 2023
December 25th 2023

Top 5 Most-Read Lung Cancer Articles of 2023

Julia Bonavitacola
Our most-read content that featured lung cancer included articles on non–small cell lung cancer, how navigation programs can increase screening rates, and a potential link between antidepressants and lung cancer risk.
Lung cancer | Image credit: Dr_Microbe - stock.adobe.com
December 14th 2023

Tarlatamab Application for SCLC Granted Priority Review by FDA

Julia Bonavitacola
The treatment developed by Amgen could be the first therapeutic option approved for third-line treatment of advanced small cell lung cancer (SCLC).
Tai chi chuan | Image credit: Markgraf Ave - stock.adobe.com
December 13th 2023

Aerobic Exercise, Tai Chi Improved Sleep in Patients With Lung Cancer

Julia Bonavitacola
Improved psychological distress and physical function were among the benefits of doing aerobic exercise and tai chi as a patient with lung cancer.
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023

Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer

Julia Bonavitacola
A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Lung cancer illustration | Image credit: SciePro - stock.adobe.com
November 28th 2023

Early CT Screening Significantly Improves Survival in Lung Cancer

Rina Lokaj
Early CT screening leads to a 20-year lung cancer survival rate of 81%.
Hospital corridor | Image credit: VILevi - stock.adobe.com
November 23rd 2023

Trilaciclib May Reduce Hospitalization and Improve Survival in ES-SCLC

Russ Conroy
Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.
What We’re Reading: Medicaid Coverage Errors; Gender Disparities in Health Research; Improved Lung Cancer Survival Rates
November 14th 2023

What We’re Reading: Medicaid Coverage Errors; Gender Disparities in Health Research; Improved Lung Cancer Survival Rates

AJMC Staff
Up to 30 million individuals could lose Medicaid coverage; a new initiative demands increased focus on women's health issues; survey reports increased 5-year lung cancer survival rates from 2015 to 2019.
what we're reading logo
November 2nd 2023

What We’re Reading: Expanded Lung Cancer Screening Guidelines; Expert Health Insurance Advice; Patients Uber to Appointments

AJMC Staff
The American Cancer Society expanded eligibility for lung cancer screening; experts advised patients to do their research before choosing a plan from the Affordable Care Act’s insurance marketplaces; Republican-led states partnering with rideshare companies for medical appointment rides.
Lung cancer cells | Image credit: David A Litman - stock.adobe.com
November 1st 2023

Osimertinib Combo Lessens CNS Progression in EGFR NSCLC

Darlene Dobkowski, MA
Central nervous system (CNS) progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.
design of lungs with green, blue, and yellow colors
October 22nd 2023

Adding Adjuvant Nivolumab Builds on Standard of Care for Resectable NSCLC

Laura Joszt, MA
The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.
Red FDA Approved stamp on a white backgroun
October 17th 2023

FDA Grants Pembrolizumab Sixth Indication in NSCLC

Laura Joszt, MA
The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.
What We’re Reading: School Nurse Shortage; Keytruda Receives FDA Expansion; Menthol Cigarette, Flavored Cigar Ban
October 17th 2023

What We’re Reading: School Nurse Shortage; Keytruda Receives FDA Expansion; Menthol Cigarette, Flavored Cigar Ban

AJMC Staff
School nurses play an overworked and understaffed role; Merck's immunotherapy Keytruda (pembroilzumab) has been granted approval for pre- and postsurgical treatment in lung cancer; the FDA is helping to curb tobacco-related health disparities.
3rd rendered medically accurate illustration of lung cancer Stock Illustration | © Adobe Stock
October 11th 2023

Patients With Distant Recurrent NSCLC Had Better OS vs Those With De Novo Disease

Justina Petrullo
Patients with distant recurrent non–small cell lung cancer (NSCLC) had significantly better overall survival (OS) than patients who had de novo disease.
Hands holding a paper set of lungs | Image credit: SewcreamStudio - stock.adobe.com
October 4th 2023

Takeda to Voluntarily Withdraw Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

Kristi Rosa
Following discussions with FDA, Takeda will voluntarily withdraw mobocertinib in the United States for adult patients with EGFR exon 20 insertion mutation–positive, locally advanced or metastatic non–small cell lung cancer (NSCLC) based on the outcomes of the phase 3 EXCLAIM-2 trial.
Health Care Costs Stock Photos and Images - 123RF | © 123RF Stock Photos
September 26th 2023

Adjuvant Therapy for Early-Stage NSCLC After Surgery Yields Lower Costs

Justina Petrullo
Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.
DNA double helix molecules and chromosomes | © Adobe Stock
September 18th 2023

HR+ NSCLC More Common in Women; EGFR, KRAS More Common in HR+ NSCLC

Justina Petrullo
Women have a higher likelihood of having hormone receptor (HR+) non-small cell lung cancer (NSCLC) than men, and mutations of EGFR and KRAS were more common in HR+ NSCLC in a recent study.
Dr. Pasi A. Jänne from the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Mass.
September 12th 2023

Osimertinib Plus Chemotherapy Demonstrated Greater PFS Benefit in Patients With EGFRm Advanced NSCLC Than Osimertinib Alone

Justina Petrullo
Osimertinib administered in addition to chemotherapy showed more progression-free survival (PFS) benefit than just osimertinib in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC).
Woman Suffering an Anxiety Attack Alone in the Night Stock Photo | Image Credit iStockPhoto.com
September 12th 2023

Patients With NSCLC Describe Experiences of Symptoms on Daily Life

Justina Petrullo
Patients with advanced or metastatic non–small cell lung cancer (NSCLC) were able to specify a 1-point threshold when describing meaningful symptom change, for better or worse, that helped illustrate their symptom experience.
A graphic of a pair of lungs
September 6th 2023

Liquid Biopsy Might Be Useful in the Detection of Colorectal, Lung Cancer

Justina Petrullo
Investigators wanted to analyze the diagnostic performance of methylation-sensitive restriction enzyme digestion followed by sequencing using cell-free DNA and explore the cancer signal origin of the cancer using DNN analyses for colorectal and lung cancers.
A Black couple listens to a health care provider
September 3rd 2023

Elimination of PFTs Might Worsen Disparities for African American Patients With Lung Cancer

Justina Petrullo
Removal of pulmonary function tests (PFTs) might exacerbate disparities for African American patients with lung cancer.
A scientist is adding blood to vials
August 22nd 2023

Certain Immune Cell Types Linked With ICI Response in Patients With NSCLC

Justina Petrullo
Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).
skeleton with lungs highlighted
August 21st 2023

Perspectives on Immunotherapy in the Treatment of Advanced NSCLC: A Stakeholder Interchange Report

graphic of a brain
August 19th 2023

Machine-Learning Models May Help Determine Brain Metastasis Risk in Patients With NSCLC

Justina Petrullo
Patients with non-small cell lung cancer (NSCLC) with a high risk of brain metastases might feasibly be identified through machine-learning models, according to a recent study.
graphic image of a human body showing lungs with cancer
August 17th 2023

Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC

Jordyn Sava
Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.
United States flag patch on army clothing
August 7th 2023

The Process From Referral to LCS Is a Crucial Point Among Veterans

Justina Petrullo
The process from referral to the lung cancer screening (LCS) process is a crucial point for Black veterans and may serve as a point of improvement, according to a study.
Sagun Shrestha, MD
August 6th 2023

Changes to the SCLC Treatment Landscape Stirs Up Hope for Oncologists

Jordyn Sava
In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.
IVBM Logo
August 4th 2023

Emory’s Ticiana Leal, MD, Says Rise in Druggable Targets Boosts Importance of Biomarker Testing in NSCLC

Mary Caffrey
Coverage from the Institute for Value-Based Medicine event in Atlanta, held in partnership with Winship Cancer Institute of Emory University.
a wildfire in a forest
August 2nd 2023

Wildfire Smoke Linked to Worse Survival for Individuals With NSCLC After Surgical Resection

Justina Petrullo
Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.
radiology x-ray lung cancer: © utah51 - stock.adobe.com
July 31st 2023

Subtle Differences in NSCLC Could Help Guide Treatment Strategies

Gwen Mergian
Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).
12345678
...
9>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo